Brief: Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
23/04/2024 13:58
April 23 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA INC: INTRANASAL DELIVERY OF SPC-15 SHOWS RAPID
AND
EFFECTIVE DRUG EXPOSURE FOR PTSD THERAPY
* SILO PHARMA: NON-GLP STUDY TO BE FOLLOWED BY PIND STUDY
AND THEN
GLP STUDY, BOTH SLATED TO COMMENCE IN 2024
Source text for Eikon: ID:nGNX83JPc
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement